Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIMERVAX with adjuvanted seasonal influenza vaccine in adults ≥65 years
2023-506189-29-00Phase 2Completed
- Sponsor
- HIPRA
- Start
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and influenza comparing Coadministration: BIMERVAX + Fluad Tetra, BIMERVAX alone and Fluad Tetra alone (3 arms). Primary endpoints: Solicited local and systemic reactions through Day 7, Unsolicited local and systemic adverse events and 2 more. Started Jul 2023; status: completed.
02
Drugs
PHH-1Vinfluenza virus type B (Victoria)
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on 2023-506189-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506189-29-00.